BioWorld Spotlights Model Medicines’ Expansion Into High-Value Oncology Targets
Press Coverage
Patrick ONeill
BioWorld covered Model Medicines’ launch of oncology programs targeting AXL and BRD4, marking an important expansion of the company’s AI-driven discovery engine beyond infectious disease and into difficult-to-drug cancer biology.
Patrick ONeill
Head of Partnerships and Investor Relations
BioWorld highlighted Model Medicines’ move into oncology with programs focused on AXL and BRD4, two biologically important targets implicated across hematologic and solid tumors. The coverage followed Model Medicines’ announcement that its GALILEO™ Drug Discovery Platform had identified multiple novel chemotypes with activity against AXL and BRD4, including compounds demonstrating nanomolar or low micromolar activity in early in vitro validation studies. The article positioned the programs as an early example of how Model Medicines could apply AI-enabled discovery across broad areas of human disease, using platform-driven modeling to pursue high-value targets that have historically been challenging for traditional drug development.
